Emerging #cancer therapies such as #immunotherapy, targeted therapy, and cell therapy have advanced rapidly in recent years. Among these, antibody-drug conjugates (#ADC), sometimes referred to as a “biological missile”, can specifically attack cancer cells without causing harm to normal cell tissues. This approach considerably increased anti-tumor specificity resulting in reduced toxic side effects.
syngeneic mouse models ADCs are typically made up of fully humanized monoclonal antibodies, cytotoxic agent, and linkers that combine the properties of a targeted and chemotherapeutic agent to deliver precision cancer therapy. ADC was first proposed by Paul Ehrlich, a pioneer of immunology, over a century ago. Since the first ADC medicine, #Mylotarg, was introduced in 2000, ADC technology has gone through three generations. Fourteen ADC drugs have been approved for marketing as single agents or in combination for treating various solid or hematologic tumors. Nearly 90 ADC drugs have entered clinical trials for multiple therapeutic areas.
Given the rise of ADC drug development, #NMPA’s Center for Drug Evaluation (#CDE) recently issued the “Technical Guidelines for ADC Non-Clinical Studies”. This outlines the requirements for research strategies and basic framework for ADC drugs in the preclinical phase.
To support the #preclinical evaluation of ADC drugs, GemPharmatech offers a one-stop solution for in vivo/in vitro drug efficacy testing, #pharmacokinetic evaluation, and #toxicological safety assessment (non-GLP).
GemPharmatech is devoted to supporting the preclinical research needs of ADC drug development by generating a library of humanized mouse models using #geneediting technology. We are committed to offering customizable, comprehensive solutions for the preclinical phase of drug development.
#GemPharmatech #biotech #mousemodels #cancertherapies #targetedtherapy #celltherapy
#antibodydrugconjugates #antibody #antitumor #toxicsideeffect #monoclonalantibodies #Nonclinical